AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) shares were down 1.6% during trading on Friday . The company traded as low as $25.91 and last traded at $26.36, with a volume of 221,166 shares trading hands. The stock had previously closed at $26.79.

A number of research analysts have recently commented on AMAG shares. Leerink Swann dropped their price objective on shares of AMAG Pharmaceuticals from $45.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, May 4th. JPMorgan Chase & Co. reaffirmed a “hold” rating and set a $37.00 price objective on shares of AMAG Pharmaceuticals in a research note on Thursday, May 5th. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Jefferies Group reaffirmed a “buy” rating on shares of AMAG Pharmaceuticals in a research note on Wednesday, May 4th. Finally, Robert W. Baird dropped their price objective on shares of AMAG Pharmaceuticals from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Monday, March 28th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $38.20.

The firm has a 50-day moving average price of $23.92 and a 200-day moving average price of $23.54. The company has a market capitalization of $894.53 million and a PE ratio of 86.52.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.11 by $0.17. The company earned $117.60 million during the quarter, compared to analysts’ expectations of $124.83 million. During the same period in the prior year, the company posted $1.17 earnings per share. The company’s quarterly revenue was up 41.9% on a year-over-year basis. On average, equities analysts forecast that AMAG Pharmaceuticals Inc. will post $5.20 earnings per share for the current year.

Several large investors have recently bought and sold shares of AMAG. Cornerstone Capital Management Holdings LLC. increased its stake in AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock worth $1,498,000 after buying an additional 42,208 shares during the period. Rhumbline Advisers increased its stake in AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock worth $1,131,000 after buying an additional 3,420 shares during the period. Bank of Montreal Can increased its stake in AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock worth $2,287,000 after buying an additional 73,152 shares during the period. BNP Paribas Arbitrage SA increased its stake in AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock worth $1,893,000 after buying an additional 3,903 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in AMAG Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 397,816 shares of the specialty pharmaceutical company’s stock worth $12,010,000 after buying an additional 8,435 shares during the period.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.